drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (autologous CAR T cells)
drug_description
An autologous, genetically engineered BCMA-targeted CAR T-cell therapy designed to deplete BCMA-expressing plasmablasts and long-lived plasma cells to reduce pathogenic autoantibodies in refractory lupus nephritis and IgG4-related disease.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a BCMA-targeted chimeric antigen receptor. After infusion, these CAR T cells recognize and kill BCMA-expressing plasmablasts and long-lived plasma cells, depleting autoantibody-producing cells and reducing pathogenic antibodies in refractory lupus nephritis and IgG4-related disease.
drug_name
PRG-1801
nct_id_drug_ref
NCT06497387